Aeolus Pharmaceuticals Inc (AOLS.PK) Key Developments | Reuters.com
Edition:
United States

Analyst Research

Report Title Price
Provider : Pechala's Reports
$25.00
Provider : Reuters Investment Profile
$20.00
Provider : Wright Reports
$75.00
Provider : GlobalData
$300.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Aeolus Pharmaceuticals Inc files investigational new drug application with US FDA


Wednesday, 20 Aug 2014 01:00pm EDT 

Aeolus Pharmaceuticals Inc:Files Investigational New Drug Application (IND) with Division of Medical Imaging Products of US Food and Drug Administration (FDA) to enable initiation of a phase 1 study of AEOL 10150 in healthy human volunteers.New phase 1 study is designed as first step in meeting requirements for approval of drug as medical countermeasure for lung damage due to radiation exposure (Lung-ARS) under FDA's Animal Rule.Aeolus is developing AEOL 10150 for this indication under five-year contract with Biomedical Advanced Research and Development Authority (BARDA) valued at up to $118 mln. 

Latest Developments forAeolus Pharmaceuticals Inc

Company Quote

0.1735
-0.0116 -6.27%
24 Jun 2016